国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
17期
2131-2134
,共4页
潘志信%李飞%刘青阁%叶虹
潘誌信%李飛%劉青閣%葉虹
반지신%리비%류청각%협홍
急性脑梗死%依达拉奉%神经节苷脂
急性腦梗死%依達拉奉%神經節苷脂
급성뇌경사%의체랍봉%신경절감지
Acute cerebral infarction%Edaravone%Ganglioside
目的 探讨依达拉奉联合神经节苷脂治疗急性脑梗死的临床疗效.方法 选取2007年6月至2010年6月急性脑梗死患者138例,并随机分为观察组69例与对照组69例,对照组给予常规治疗并给予阿司匹林抗血小板,聚集、控制血压、血糖及脱水降颅压及保护脑细胞、改善循环、使用甘露醇、丹参、胞二磷胆碱等治疗;观察组在常规治疗的基础上加用依达拉奉联合神经节苷脂.所有病例于治疗前后用美国国立卫生院卒中患者神经机能缺损评分量表(National Institutes of Health Stroke,NIHSS)评分.结果 治疗2ld后,观察组总显效率为82.61%,总有效率为94.41%;对照组总显效率为31.88%,总有效率为39.13%,两组比较差异有统计学意义(P<0.05),观察组NIHSS评分与对照组比较差异有统计学意义(P<0.05).结论 依达拉奉联合神经节苷脂治疗急性脑梗死不但安全有效,而且能更好地提高神经功能恢复,对脑组织有显著保护作用,并降低致残率,提高患者生活质量.
目的 探討依達拉奉聯閤神經節苷脂治療急性腦梗死的臨床療效.方法 選取2007年6月至2010年6月急性腦梗死患者138例,併隨機分為觀察組69例與對照組69例,對照組給予常規治療併給予阿司匹林抗血小闆,聚集、控製血壓、血糖及脫水降顱壓及保護腦細胞、改善循環、使用甘露醇、丹參、胞二燐膽堿等治療;觀察組在常規治療的基礎上加用依達拉奉聯閤神經節苷脂.所有病例于治療前後用美國國立衛生院卒中患者神經機能缺損評分量錶(National Institutes of Health Stroke,NIHSS)評分.結果 治療2ld後,觀察組總顯效率為82.61%,總有效率為94.41%;對照組總顯效率為31.88%,總有效率為39.13%,兩組比較差異有統計學意義(P<0.05),觀察組NIHSS評分與對照組比較差異有統計學意義(P<0.05).結論 依達拉奉聯閤神經節苷脂治療急性腦梗死不但安全有效,而且能更好地提高神經功能恢複,對腦組織有顯著保護作用,併降低緻殘率,提高患者生活質量.
목적 탐토의체랍봉연합신경절감지치료급성뇌경사적림상료효.방법 선취2007년6월지2010년6월급성뇌경사환자138례,병수궤분위관찰조69례여대조조69례,대조조급여상규치료병급여아사필림항혈소판,취집、공제혈압、혈당급탈수강로압급보호뇌세포、개선순배、사용감로순、단삼、포이린담감등치료;관찰조재상규치료적기출상가용의체랍봉연합신경절감지.소유병례우치료전후용미국국립위생원졸중환자신경궤능결손평분량표(National Institutes of Health Stroke,NIHSS)평분.결과 치료2ld후,관찰조총현효솔위82.61%,총유효솔위94.41%;대조조총현효솔위31.88%,총유효솔위39.13%,량조비교차이유통계학의의(P<0.05),관찰조NIHSS평분여대조조비교차이유통계학의의(P<0.05).결론 의체랍봉연합신경절감지치료급성뇌경사불단안전유효,이차능경호지제고신경공능회복,대뇌조직유현저보호작용,병강저치잔솔,제고환자생활질량.
Objective To explore the efficacy of edaravone combined with ganglioside for acute cerebral infarction. Methods 138 patients with acute cerebral infarction from June 2007 to June 2010 were randomly divided into study group and control group, 69 patients for each group. The control group received conventional therapy, aspirin for controlling blood platelets, control of blood pressure and sugar and water to intracranial hypotension, protection of cerebral cells, and improvement of circulation, mannitol, salvia miltiorrhiza, andciticoline; The study group on the edaravone plus ganglioside besides conventional therapy.All the patients were assessed using National Institutes of Health Stroke before and after treatment.Results21 days after therapy, the overall response rate was 82.61%in the study group and 31.88% in the control group, and the total effective rate was 94.41% and 39.13%, respectvely: there was a statistical difference between the two groups (P<0.05). Scores for NIHSS differed significantly between the two groups (P<0.05).Conclusions Edaravone combined with ganglioside for acute cerebral infarction is safe and effective and can increase the recovery of nerve function, protect the cerebral tissue, reduce disability rate, and improve the quality of life.